Research and Markets has announced the addition of the "Intravenous-to-Subcutaneous Drug Markets" report to their offering.
The number of drugs based on biologicals continues to grow at an increasingly rapid rate. Because of their physical properties and the relatively high administration volumes often required to achieve the desired therapeutic effect, the majority are developed and launched for intravenous administration. This is creating a burgeoning demand for infusion facilities, personnel and equipment.
The relative complexity, costs and patient logistics associated with IV infusion relative to other routes of administration is creating interest in post-launch re-engineering of IV drugs to allow them to be administered subcutaneously. A number of technology approaches are currently being employed to accomplish this migration. By pursuing intravenous-to-subcutaneous drug markets, drug owners are finding they can achieve a number of competitive advantages.
What You Will Learn:
Key Topics Covered:
1. Executive Summary
2. The Market Opportunity
3. Market Sector Dynamics
4. Intravenous-to-Subcutaneous Technology
5. IV-to-SC - Drug Product Analysis
6. IV-to-SC - Therapeutic Sector Analysis
7. Market Factors
8. Regulatory Issues
9. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/ncfr24/intravenoustosub
Related Topics: Infusions and Injectables
View source version on businesswire.com: http://www.businesswire.com/news/home/20160826005449/en/Business Wire
Last updated on: 26/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.